

The word "XENON" is displayed in large, white, sans-serif capital letters against a dark blue background with a faint, abstract pattern of interconnected lines and nodes, resembling a neural network or molecular structure.

XEN1101: A Novel, Next- Generation KCNQ2 Modulator for the Treatment of Epilepsy

Y. Paul Goldberg, MBChB, Ph.D., FRCPC
Xenon Pharmaceuticals, Inc.

Eilat XIV Meeting | May 15, 2018 | Madrid, Spain

Forward Looking Statement/Safe Harbor

This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact could be deemed forward-looking, including, but not limited to, statements regarding our expectations regarding the timing of and results from clinical trials and pre-clinical development activities, including those related to XEN1101 and our other product candidates, the potential efficacy, safety profile, future development plans, addressable market, regulatory success and commercial potential of XEN1101 and our other product candidates, the anticipated timing of IND, or IND equivalent, submissions and the initiation of future clinical trials for XEN1101 and our other product candidates, the efficacy of our clinical trial designs, our ability to successfully develop and achieve milestones in the XEN1101 and other development programs, the anticipated benefits of the unique mechanisms of action of XEN1101, the design of our clinical trials and anticipated enrollment, the potential for XEN1101 to support once daily dosing, the ability to replicate the Phase 1 data of XEN1101 in a head-to-head trial with ezogabine, and the progress and potential of our other ongoing development programs.

These statements are based on estimates and information available to us at the time of this presentation and are not guarantees of future performance. Actual results could differ materially from our current expectations as a result of many factors, including but not limited to [promising results in early clinical trials may not be replicated in subsequent clinical trials; clinical trials may not demonstrate safety and efficacy of any of our or our collaborators' product candidates; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; the impact of competition; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission and the securities commissions in British Columbia, Alberta and Ontario. Except as required by law, we assume no obligation and do not intend to update these forward-looking statements or to conform these statements to actual results or to changes in our expectations.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

NOTE: Comparisons of XEN1101 and ezogabine are based on results in published literature, not based on data resulting from head-to-head trials, and are not direct comparisons of safety or efficacy. Different protocol designs, trial designs, patient selection and populations, number of patients, trial endpoints, trial objectives and other parameters that are not the same between the relevant trials may cause any comparisons of results from different trials to be unreliable.


XEN1101: Best-in-Class KCNQ2 Modulator

- Same mechanism of action as ezogabine, but with substantial improvements
 - More potent *in vitro* and *in vivo*
 - Improved PK
 - Once daily dosing and predict better tolerability
 - No predicted pigmentation liability
 - Does not form pigmented dimers
- Modulating cortical activity in healthy volunteers (TMS)
 - Within predicted efficacious exposures
- Safe and well tolerated in ongoing Phase 1 study

Presentation Overview


- Background on K_v7.2 and XEN1101
- Phase 1 Trial Design and Results
 - PK, Safety
 - TMS Pilot Study
- Ongoing Studies and Future Development Plans
- Summary

KCNQ2 is a Highly Genetically Validated Target



M-Current Gradient Correlates with Disease Severity

XEN1101 Based on Proven Mechanism of Action




K_v7.2 Attenuates Neuronal Hyper-Excitability

Multiple Predicted Benefits of XEN1101 over Ezogabine


Improvement	Key Difference to Ezogabine / Predicted Impact
Chemistry	• No dimerization or oxidative color changes • Predict no skin and retinal pigmentation
Potency	• 10-50X greater <i>in vitro</i> potency on Kv7.2/3
Pharmacokinetic (PK)	• Once daily dosing vs TID • Predict better CNS tolerability
Pre-clinical Efficacy & TMS Signal	• Broadly effective at lower doses in multiple preclinical epilepsy models • Superior TMS signal of cortical activity in humans at a significantly lower dose

Increased Potency of XEN1101



Assay	EC ₅₀	Function
K _V 7.2/K _V 7.3	27 nM	CNS
K _V 7.3/K _V 7.5	94 nM	CNS
K _V 7.4	113 nM	Bladder

Improved Therapeutic Index of XEN1101




Metabolism Suggests Minimal Risk for Drug-Drug Interactions

- Metabolism
 - Highly stable in liver microsomes and hepatocytes
 - No risk of DDI through inhibition of CYP450 enzymes
 - No inhibition of CYP1A2, 2C9, 2C19, 2D6 & 3A4 tested at 3 μ M
 - No significant time-dependent inhibition of CYP1A2, 2C9, 2C19, 2D6 & 3A4
 - Very low risk of susceptibility to DDI from other CYP inducers
 - Not metabolized by CYP1A2, 2B6, 2C8, 2C9, 2C19 & 2D6
 - Minor role of CYP3A4 in metabolism
 - Not a CYP450 inducer
 - No significant induction of PXR at 1 μ M


Clinical Overview of XEN1101

- Phase 1 protocol: Adaptive integrated design
 - SAD/MAD/Food Effect (FE) study
 - Pilot TMS study (Phase 1a)
 - TMS Cross-over study (Phase 1b)
- Planning Phase 2 clinical trial in Adult Focal Epilepsy
- Pediatric development options currently being evaluated
 - Focal seizure population
 - Explore precision medicine in KCNQ2 population

XEN1101 Phase 1 Trial Design




XEN1101 Single Ascending Dose




Long Half-Life Consistent with Once Daily Dosing

XEN1101 Repeat Dosing for 7 Days




Achieve Steady State Plasma Levels at Approximately 7 days

Food Enhances XEN1101 Exposure



Cross-Over Design Food Effect

Chronic Low Daily Dosing Achieves Exposures Required for TMS and Pre-Clinical Efficacy



No Signal of Urinary Retention in Clinic to Date

- Single doses of XEN1101: 5-30 mg
 - No urinary retention or hesitation AEs noted in 28 volunteers
 - C_{max} range up to 104 ng/mL
- Multiple doses of XEN1101: 15 mg QD for 7 days
 - No urinary retention or hesitation AEs noted in 6 volunteers
 - C_{max} range up to 57.7 ng/mL
 - Post-void residual volume bladder ultrasound normal

Post Void Residual Volume Evaluation in MAD		
Study Day	XEN1101 (N = 6)	Placebo (N = 2)
Pre-dose	37.0 ± 27.8 mL	28.0 ± 15.6 mL
Day 7	13.2 ± 5.6 mL	8.5 ± 0.7 mL


Interim Preliminary Safety Summary

- Ongoing study, evaluated SAD: 5, 15, 20, 30 mg, MAD: 15 mg
- No SAEs or deaths
- No clinically significant ECG or Laboratory findings
- Majority of AEs were mild and resolved spontaneously
 - Most common AEs were headache, dizziness, and drowsiness
 - One severe AE: vasovagal reaction following a blood draw and standing
- Post void residual volume (MAD) not increased; no chromaturia
- Overall safe and well tolerated


Transcranial Magnetic Stimulation (TMS)

- TMS uses a magnetic pulse to stimulate human motor cortex
 - Response can be measured with
 - EMG (motor threshold for finger twitch)
 - EEG (characteristic response pattern)
- TMS is used to assess cortical excitability in response to AEDs in both volunteers and patients
- Provides an opportunity for an early indicator of pharmacological effects consistent with anti-epileptic activity in human volunteers

TMS EMG




TMS-evoked Motor Potentials (MEPs)




Rogasch et al, 2013 Schiz Bull

TMS EEG




TMS-evoked EEG Potentials (TEPs)



Premoli et al., 2014 Journal of Neuroscience

Prior TMS-EMG Cross-Over Study Using Ezogabine

- Double-blind, placebo-controlled cross-over study
- 15 healthy subjects
- Single 400 mg dose of ezogabine
- TMS-EMG performed at $C_{\max}$ of 2 hours
 - No TMS-EEG performed
- Resting Motor Threshold (RMT) increased
 - $2.4 \pm 3.6 \%$



Osseman et al, *Epilepsy Res*, 126, 78, 2016

TMS Strategy for XEN1101

Goal:

- Seeking a marker of early target engagement in humans


Objectives:

- Compare magnitude of effects of XEN1101 vs ezogabine
- Provide preliminary evidence for CNS target engagement
- Determine dose and sample size for robust double-blind, placebo-controlled, TMS-EMG/EEG cross-over study

XEN1101 Open-Label Pilot TMS Study


- 8 male subjects
- Entered pilot TMS study after completing SAD cohort
- Three dose levels (10, 15, 20 mg) evaluated, open label
- TMS-EMG and TMS-EEG evaluations compared to baseline

XEN1101: Substantial RMT Response at Low Dose



TMS-EMG Effect of XEN1101 Observed at 20 mg vs Ezogabine at 400 mg


TMS-EEG: Provides Biomarkers of Physiological Processes



Premoli et al., 2014 Journal of Neuroscience

XEN1101 Shows Robust Response & Emerging EEG Signature


TMS-EEG of XEN1101 20 mg Dose



Pattern of Reduced N100 and P180 Amplitudes

TMS-EEG Evoked Potentials						
20 mg	Pre		Post 2h		Post 4h	
	N100	P180	N100	P180	N100	P180
mean	-3.87	1.61	-2.23	0.54	-2.02	-0.31
SD	0.77	0.73	1.43	1.21	1.39	0.70

Topographical Map 180 ms



Statistically Significant XEN1101 Suppression at 4 hours ($p < 0.01$)

Summary of Pilot TMS Results


- EMG
 - Signal at 10 and 15 mg, with robust response at 20 mg
 - TMS-EMG effect of XEN1101 observed at 20 mg vs ezogabine at 400 mg
- EEG
 - 20 mg dose shows statistically significant modulating activity, with reproducible and specific pattern of response
 - Reduced amplitudes of N100 and P180 peaks
 - Effects on evoked potentials similar in magnitude to lamotrigine and levetiracetam
- Well-powered, placebo-controlled cross-over nearing completion
 - N=15-20
 - 20 mg

Summary of XEN1101 Interim Phase 1 / Pilot TMS Results

- XEN1101 has a PK profile consistent with once a day dosing
- Mild transient AE profile consistent with MOA (e.g., dizziness, sedation)
- Majority of AEs mild except a vasovagal reaction during standing orthostatic BP test immediately after blood draw
- No safety signals in ECG or Safety Labs; no SAEs
- Exposure enhanced by food
- Steady state plasma levels reached at ~ 7 days
- Low inter-individual exposure with repeat dose
- Robust TMS response detected at 20 mg
- TMS cross-over study ongoing at 20 mg

XEN1101 Phase 1b TMS Cross-Over Study

- To evaluate the safety, tolerability, pharmacokinetics and TMS effects of XEN1101 in a double-blind, placebo-controlled, cross-over study
 - London, UK (King's College Hospital)
 - Male healthy volunteers (18-55 years)
 - Single dose, 20 mg
 - N = 15-20
 - Placebo-controlled, double-blind
 - Cross-over



XEN1101 Phase 2 Clinical Planning

- Proposed plans include a Phase 2 clinical trial (H2:18 start) in adult patients with focal seizures
- Pediatric development options currently being evaluated
 - Focal seizure population
 - Precision medicine in KCNQ2 population

XEN1101 Summary

- Best-in-class $K_v7.2$ modulator
- Highly clinically, pharmacologically and genetically validated mechanism
- Substantial improvement over ezogabine
 - Pigmentation issue appears resolved
 - More potent and predicted improved TI
 - Predict lower CNS-related AEs due to QD dosing with low peak to trough ratio
- Phase 1 clinical trial and TMS placebo-controlled cross-over study ongoing
 - Interim data suggests XEN1101 is safe and well tolerated
 - Exposure within predicted efficacy range at low doses
 - Oral PK supports QD dosing
 - Robust TMS signal with increased RMT and a distinct N100 and P180 pattern at 20 mg
- AED polypharmacy, without predicted DDI liability
- Phase 2 start expected in second half of this year

Acknowledgements / Contributors

King's College London

- Isabella Premoli
- Mark Richardson
- Pierre Rossini
- Eugenio Abela
- Kristina Posadas

Richmond Pharmacology Ltd.

1st Order Pharmaceuticals

- Chris Crean

Xenon Pharmaceuticals

- Greg Beatch
- Catherine Leung
- Jay Cadieux
- Rostam Namdari
- Heather Kato
- Ying Man
- Charles Cohen
- Jim Empfield
- Paul Bichler
- Robin Sherrington
- Simon Pimstone
- Ernesto Aycardi